Revvity raises 2026 forecast after Q3 profit tops estimates

Revvity (RVTY) topped third-quarter profit and revenue estimates and raised its full-year forecast, the company said in its results release on Nov. 3.

Adjusted earnings per share from continuing operations were $1.38, above the $1.33 consensus estimate. Revenue was $728.90 million, above a $712.12 million estimate.

Here's how the company did:

• Adjusted EPS: $1.38 per share vs. $1.18 a year earlier, above the $1.33 consensus estimate
• Revenue: $728.90 million vs. $698.9 million a year earlier, above the $712.12 million estimate

GAAP earnings per share from continuing operations were $0.56, up from $0.41 a year earlier. GAAP operating income from continuing operations was $95 million, compared with $82 million a year earlier.

Adjusted operating income was $209 million, up from $182 million, and the adjusted operating margin was 28.7%, compared with 26.1%.

“Our exceptional third quarter performance demonstrates the momentum building across Revvity,” said Prahlad Singh, president and chief executive officer of Revvity. “With end market conditions continuing to improve, a strong pipeline of innovation, and the benefits of our transformation increasingly evident in our results, Revvity is extremely well positioned to capitalize on the opportunities ahead.”

On a pro forma basis, which excludes China IDX, revenue was $710 million, up from $660 million a year earlier. Pro forma organic revenue grew 7%. Pro forma adjusted EPS was $1.37, compared with $1.13.

2026 guidance

For the full year, on a pro forma basis, the company forecasts total revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted EPS of $5.40 to $5.45.

That compares with the forecast it gave on Aug. 4, when it expected total revenue of $2.83 billion to $2.86 billion, pro forma organic revenue growth of 4% to 5%, and pro forma adjusted EPS of $5.30 to $5.40.

Segment results

Life Sciences revenue was $380 million, up from $343 million a year earlier. Pro forma revenue rose 11%, and pro forma organic revenue rose 9%. Adjusted operating income was $119 million, up from $101 million, and the adjusted operating margin was 31.5%, compared with 29.5%.

Diagnostics revenue was $349 million, down from $356 million a year earlier. Pro forma revenue rose 4%, and pro forma organic revenue rose 5%. Adjusted operating income was $104 million, up from $89 million, and the adjusted operating margin was 29.9%, compared with 25.1%.

China IDX sale

Revvity agreed on July 31, 2026, to sell its Immunodiagnostics business in China, which the company calls China IDX, for up to $200 million, subject to adjustments and conditions. The company said the business represented about 6% of its total revenue in fiscal 2025.

The company said it expects the sale to close by the end of 2027, subject to customary closing conditions and regulatory approvals. Its pro forma statements show a $55 million loss on the probable disposition, including tax impacts.

Costs and charges

Restructuring and other charges were $28.4 million in the quarter, compared with $9.9 million a year earlier. Amortization of intangible assets was $84.7 million.

Investor Day

Revvity will hold its 2026 Investor Day on Nov. 13, beginning at 9:00 a.m. ET. Management presentations will cover the company's business initiatives and financial outlook.